Ansofaxine

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Ansofaxine
Ansofaxine.svg
Systematic (IUPAC) name
4-[2-(Dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenyl 4-methylbenzoate
Clinical data
Routes of
administration
Oral
Identifiers
ATC code None
ChemSpider 13114670
Chemical data
Formula C24H31NO3
Molecular mass 381.508 g/mol
  • Cc1ccc(cc1)C(=O)Oc2ccc(cc2)C(CN(C)C)C3(CCCCC3)O
  • InChI=1S/C24H31NO3/c1-18-7-9-20(10-8-18)23(26)28-21-13-11-19(12-14-21)22(17-25(2)3)24(27)15-5-4-6-16-24/h7-14,22,27H,4-6,15-17H2,1-3H3
  • Key:QKYBZJLEMOZFFU-UHFFFAOYSA-N

Ansofaxine hydrochloride (INN) (former developmental code names LY03005, LPM570065), also known as 4-methylbenzoate desvenlafaxine hydrochloride, is a serotonin-norepinephrine-dopamine reuptake inhibitor that is under development by Luye Pharma Group for the treatment of major depressive disorder.[1][2][3] It is described as an SNDRI and prodrug to desvenlafaxine.[1] However, unlike desvenlafaxine, which has in vitro IC50 values of 53 nM and 538 nM for inhibition of serotonin and norepinephrine reuptake, respectively, ansofaxine has respective in vitro IC50 values of 723 nM, 763 nM, and 491 nM for serotonin, norepinephrine, and dopamine reuptake inhibition.[1] As of March 2015, the drug is in phase I clinical trials.[3][4]

See also

References

  1. 1.0 1.1 1.2 Lua error in package.lua at line 80: module 'strict' not found.
  2. Lua error in package.lua at line 80: module 'strict' not found.
  3. 3.0 3.1 Completion of Phase 1 Clinical Studies of Ansofaxine Hydrochloride Extended Release Tablets (LY03005) in the U.S.
  4. Ansofaxine - AdisInsight


<templatestyles src="Asbox/styles.css"></templatestyles>